The dialogue of the host-parasite relationship: Leishmania spp. and Trypanosoma cruzi Infection

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  De Morais, Carlos Gustavo Vieira ^a   Castro Lima, Ana Karina ^a   Terra, Rodrigo ^a,b   Dos Santos, Rosiane Freire ^a   Da Silva, Silvia Amaral Gonçalves ^a   Dutra, Patrícia Maria Lourenço ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Programa de Pos Graduacao em Fisiopatologia Clinica e Experimental FCM UERJ Pavilhão Américo Piquet Carneiro   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHAGAS DISEASE; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PARASITE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TRYPANOSOMA CRUZI; IMMUNOLOGY; PARASITOLOGY; PATHOGENICITY;

PROTOZOA; TRYPANOSOMA CRUZI; TRYPANOSOMATIDAE;

ANTIGEN;

ANTIGENS; CHAGAS DISEASE; HOST-PARASITE INTERACTIONS; HUMANS; LEISHMANIA; LEISHMANIASIS; TRYPANOSOMA CRUZI;

EID: 84930613717     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/324915     Document Type: Review

References (233)

1. J. A. Patz, T. K. Graczyk, N. Geller, and A. Y. Vittor, "Effects of environmental change on emerging parasitic diseases" International Journal for Parasitology, vol. 30, no. 12-13, pp. 1395-1405, 2000
2. D. Butler, "Lost in translation" Nature, vol. 449, no. 7159, pp. 158-159, 2007
3. R. Lainson, R. D. Ward, and J. J. Shaw, "Leishmania in phlebotomid sandflies: VI. Importance of hindgut development in distinguishing between parasites of the Leishmania mexicana and L. braziliensis complexes" Proceedings of the Royal Society of London: Biological Sciences, vol. 199, no. 1135, pp. 309-320, 1977
4. R. Killick-Kendrick, "The biology and control of phlebotomine sand flies" Clinics in Dermatology, vol. 17, no. 3, pp. 279-289, 1999
5. J. Alvar, I. D. Vélez, C. Bern et al., "Leishmaniasis worldwide and global estimates of its incidence" PLoS ONE, vol. 7, no. 5, Article ID e35671, 2012
6. WHO, "Research priorities for chagas disease, human African trypanosomiasis and leishmaniasis" Tech. Rep., TDR Disease Reference Group on Chagas Disease, 2012
7. R. da Silva and D. L. Sacks, "Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation" Infection and Immunity, vol. 55, no. 11, pp. 2802-2806, 1987
8. R. Zeledon, R. Bolanos, and M. Rojas, "Scanning electron microscopy of the final phase of the life cycle of Trypanosoma cruzi in the insect vector" Acta Tropica, vol. 41, no. 1, pp. 39-43, 1984
9. C. de Trez, S. Magez, S. Akira, B. Ryffel, Y. Carlier, and E. Muraille, "iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice" PLoS Pathogens, vol. 5, no. 6, Article ID e1000494, 2009
10. P. Kaye and P. Scott, "Leishmaniasis: complexity at the hostpathogen interface" Nature Reviews Microbiology, vol. 9, no. 8, pp. 604-615, 2011
11. L. Beattie, A. Peltan, A. Maroof et al., "Dynamic imaging of experimental Leishmania donovani-induced hepatic granulomas detects kupffer cell-restricted antigen presentation to antigen-specific CD8+ T cells" PLoS Pathogens, vol. 6, no. 3, Article ID e1000805, 2010
12. M. E. Bianchi, "DAMPs, PAMPs and alarmins: all we need to know about danger" Journal of Leukocyte Biology, vol. 81, no. 1, pp. 1-5, 2007
13. R. D. Pearson and R. T. Steigbigel, "Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes" Journal of Immunology, vol. 127, no. 4, pp. 1438-1443, 1981
14. K. P. Chang, "Leishmanicidal mechanisms of human polymorphonuclear phagocytes" The American Journal of Tropical Medicine and Hygiene, vol. 30, no. 2, pp. 322-333, 1981
15. A. B. Guimaraes-Costa, M. T. C. Nascimento, G. S. Froment et al., "Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps" Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 16, pp. 6748-6753, 2009
16. N. C. Peters, J. G. Egen, N. Secundino et al., "In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies" Science, vol. 321, no. 5891, pp. 970-974, 2008
17. U. A. Wenzel, E. Bank, C. Florian et al., "Leishmania major parasite stage-dependent host cell invasion and immune evasion" FASEB Journal, vol. 26, no. 1, pp. 29-39, 2012
18. M. A. Vannier-Santos, A. Martiny, and W. de Souza, "Cell biology of Leishmania spp.: invading and evading" Current Pharmaceutical Design, vol. 8, no. 4, pp. 297-318, 2002
19. M. Desjardins and A. Descoteaux, "Inhibition of phagolysosomal biogenesis by the Leishmania lipophosphoglycan" Journal of Experimental Medicine, vol. 185, no. 12, pp. 2061-2068, 1997
20. A. Descoteaux and S. J. Turco, "Functional aspects of the Leishmania donovani lipophosphoglycan during macrophage infection" Microbes and Infection, vol. 4, no. 9, pp. 975-981, 2002
21. E. Handman and J. W. Goding, "The Leishmania receptor for macrophages is a lipid-containing glycoconjugate" EMBO Journal, vol. 4, no. 2, pp. 329-336, 1985
22. P. Talamás-Rohana, S. D. Wright, M. R. Lennartz, and D. G. Russell, "Lipophosphoglycan from Leishmania mexicana promastigotes binds to members of the CR3, p150, 95 and LFA-1 family of leukocyte integrins" Journal of Immunology, vol. 144, no. 12, pp. 4817-4824, 1990
23. A. Descoteaux, G. Matlashewski, and S. J. Turco, "Inhibition of macrophage protein kinase C-mediated protein phosphorylation by Leishmania donovani lipophosphoglycan" The Journal of Immunology, vol. 149, no. 9, pp. 3008-3015, 1992
24. A. Holm, K. Tejle, T. Gunnarsson, K.-E. Magnusson, A. Descoteaux, and B. Rasmusson, "Role of protein kinase C for uptake of unopsonized prey and phagosomal maturation in macrophages" Biochemical and Biophysical Research Communications, vol. 302, no. 4, pp. 653-658, 2003
25. T. B. McNeely and S. J. Turco, "Requirement of lipophosphoglycan for intracellular survival of Leishmania donovani within human monocytes" Journal of Immunology, vol. 144, no. 7, pp. 2745-2750, 1990
26. G. F. Spath, L. A. Garraway, S. J. Turco, and S. M. Beverley, "The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts" Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 16, pp. 9536-9541, 2003
27. J. W. Booth, W. S. Trimble, and S. Grinstein, "Membrane dynamics in phagocytosis" Seminars in Immunology, vol. 13, no. 6, pp. 357-364, 2001
28. D. J. Hackam, O. D. Rotstein, C. Sjolin, A. D. Schreiber, W. S. Trimble, and S. Grinstein, "v-SNARE-dependent secretion is required for phagocytosis" Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 20, pp. 11691-11696, 1998
29. K. K. Huynh, J. G. Kay, J. L. Stow, and S. Grinstein, "Fusion, fission, and secretion during phagocytosis" Physiology, vol. 22, no. 6, pp. 366-372, 2007
30. L. Bajno, X.-R. Peng, A.D. Schreiber, H. P. Moore, W. S. Trimble, and S. Grinstein, "Focal exocytosis of VAMP3-containing vesicles at sites of phagosome formation" Journal of Cell Biology, vol. 149, no. 3, pp. 697-706, 2000
31. V. Braun and F. Niedergang, "Linking exocytosis and endocytosis during phagocytosis" Biology of the Cell, vol. 98, no. 3, pp. 195-201, 2006
32. D. Cox, D. J. Lee, B. M. Dale, J. Calafat, and S. Greenberg, "A Rab11-containing rapidly recycling compartment in macrophages that promotes phagocytosis" Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 680-685, 2000
33. M. Desjardins, "ER-mediated phagocytosis: a new membrane for new functions" Nature Reviews Immunology, vol. 3, no. 4, pp. 280-291, 2003
34. K. Hatsuzawa, T. Tamura, H. Hashimoto et al., "Involvement of syntaxin 18, an endoplasmic reticulum (ER)-localized SNARE protein, in ER-mediated phagocytosis"Molecular Biology of the Cell, vol. 17, no. 9, pp. 3964-3977, 2006
35. F. Niedergang, E. Colucci-Guyon, T. Dubois, G. Raposo, and P. Chavrier, "ADP ribosylation factor 6 is activated and controls membrane delivery during phagocytosis in macrophages" The Journal of Cell Biology, vol. 161, no. 6, pp. 1143-1150, 2003
36. E. R. Chapman, "How does synaptotagmin trigger neurotransmitter release? Annual Review of Biochemistry, vol. 77, pp. 615-641, 2008
37. R. Jahn, T. Lang, and T. C. Sudhof, "Membrane fusion" Cell, vol. 112, no. 4, pp. 519-533, 2003
38. I. Martinez, S. Chakrabarti, T. Hellevik, J. Morehead, K. Fowler, and N. W. Andrews, "Synaptotagmin VII regulates Ca2+-dependent exocytosis of lysosomes infibroblasts" Journal of Cell Biology, vol. 148, no. 6, pp. 1141-1149, 2000
39. C. Czibener, N. M. Sherer, S. M. Becker et al., "Ca2+ and synaptotagmin VII-dependent delivery of lysosomalmembrane to nascent phagosomes" Journal of Cell Biology, vol. 174, no. 7, pp. 997-1007, 2006
40. A. F. Vinet, M. Fukuda, and A. Descoteaux, "Theexocytosis regulator synaptotagminVcontrols phagocytosis inmacrophages" Journal of Immunology, vol. 181, no. 8, pp. 5289-5295, 2008
41. L. L. Vieira, N. Sacerdoti-Sierra, andC. L. Jaffe, "Effect ofpHand temperature on protein kinase release by Leishmania donovani" International Journal for Parasitology, vol. 32, no. 9, pp. 1085-1093, 2002
42. J.-F. Dermine, G. Goyette, M. Houde, S. J. Turco, and M. Desjardins, "Leishmania donovani lipophosphoglycan disrupts phagosome microdomains in J774 macrophages" Cellular Microbiology, vol. 7, no. 9, pp. 1263-1270, 2005
43. M. E. Winberg, A. Holm, E. Sarndahl et al., "Leishmania donovani lipophosphoglycan inhibits phagosomal maturation via action on membrane rafts" Microbes and Infection, vol. 11, no. 2, pp. 215-222, 2009
44. A. F. Vinet, M. Fukuda, S. J. Turco, and A. Descoteaux, "The Leishmania donovani lipophosphoglycan excludes the vesicular proton-ATPase from phagosomes by impairing the recruitment of Synaptotagmin V" PLoS Pathogens, vol. 5, no. 10, Article ID e1000628, 2009
45. A. F. Vinet, S. Jananji, S. J. Turco, M. Fukuda, and A. Descoteaux, "Exclusion of synaptotagmin V at the phagocytic cup by Leishmania donovani lipophosphoglycan results in decreased promastigote internalization" Microbiology, vol. 157, no. 9, pp. 2619-2628, 2011
46. B. A. P. Phan, M. A. Laflamme, A. Stempien-Otero, A. P. Limaye, F. S. Buckner, and W.C. Levy, "ConfirmationofChagas' cardiomyopathy following heart transplantation" Heart and Vessels, vol. 21, no. 5, pp. 325-327, 2006
47. R. Y. Dodd, E. P. Notari, and S. L. Stramer, "Current prevalence and incidence of infectious disease markers and estimated" Transfusion, vol. 42, no. 8, pp. 975-979, 2002
48. G. Punukollu, R. M. Gowda, I. A. Khan, V. S. Navarro, and B. C. Vasavada, "Clinical aspects of the Chagas' heart disease" International Journal of Cardiology, vol. 115, no. 3, pp. 279-283, 2007
49. N. Yoshida, "Trypanosoma cruzi infection by oral route: how the interplay between parasite and host components modulates infectivity" Parasitology International, vol. 57, no. 2, pp. 105-109, 2008
50. A. R. L. Teixeira, N. Nitz, M. C. Guimaro, C. Gomes, and C. A. Santos-Buch, "Chagas disease" PostgraduateMedical Journal, vol. 82, no. 974, pp. 788-798, 2006
51. N. Yoshida, S. Favoreto Jr., A. T. Ferreira, and P. M. Manque, "Signal transduction induced in Trypanosoma cruzi metacyclic trypomastigotes during the invasion of mammalian cells" Brazilian Journal ofMedical and Biological Research, vol. 33, no. 3, pp. 269-278, 2000
52. S. N. J. Moreno and R. Docampo, "Calcium regulation in protozoan parasites" Current Opinion in Microbiology, vol. 6, no. 4, pp. 359-364, 2003
53. N. W. Andrews, "Lysosomes and the plasma membrane: trypanosomes reveal a secret relationship" Journal of Cell Biology, vol. 158, no. 3, pp. 389-394, 2002
54. M. C. Fernandes, A. R. Flannery, N. Andrews, and R. A. Mortara, "Extracellular amastigotes of Trypanosoma cruzi are potent inducers of phagocytosis in mammalian cells" Cellular Microbiology, vol. 15, no. 6, pp. 977-991, 2013
55. B. A. Burleigh and A. M. Woolsey, "Cell signalling and Trypanosoma cruzi invasion" Cellular Microbiology, vol. 4, no. 11, pp. 701-711, 2002
56. B. A. Burleigh, "Host cell signaling and Trypanosoma cruzi invasion: do all roads lead to lysosomes? Science's STKE, vol. 2005, article pe36, 2005
57. N. Yoshida, "Molecular basis of mammalian cell invasion by Trypanosoma cruzi" Anais da Academia Brasileira de Ciencias, vol. 78, no. 1, pp. 87-111, 2006
58. E. V. Caler, S. Chakrabarti, K. T. Fowler, S. Rao, and N. W. Andrews, "The exocytosis-regulatory protein synaptotagmin VII mediates cell invasion by Trypanosoma cruzi" Journal of Experimental Medicine, vol. 193, no. 9, pp. 1097-1104, 2001
59. K. L. Caradonna and B. A. Burleigh, "Mechanisms of host cell invasion by Trypanosoma cruzi" Advances in Parasitology, vol. 76, pp. 33-61, 2011
60. A. O. Amer and M. S. Swanson, "A phagosome of one's own: a microbial guide to life in the macrophage" Current Opinion in Microbiology, vol. 5, no. 1, pp. 56-61, 2002
61. S. S. C. Rubin-de-Celis, H. Uemura, N. Yoshida, and S. Schenkman, "Expression of trypomastigote trans-sialidase in metacyclic forms of Trypanosoma cruzi increases parasite escape from its parasitophorous vacuole" CellularMicrobiology, vol. 8, no. 12, pp. 1888-1898, 2006
62. J. Neres, R. A. Bryce, and K. T. Douglas, "Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease" Drug Discovery Today, vol. 13, no. 3-4, pp. 110-117, 2008
63. J. Neres, M. L. Brewer, L. Ratier et al., "Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening" Bioorganic&Medicinal Chemistry Letters, vol. 19, no. 3, pp. 589-596, 2009
64. H. C. Barros, S. D. A. Silva et al., "Release of membrane-bound trails by Trypanosoma cruzi amastigotes ontomodified surfaces and mammalian cells" Journal of Eukaryotic Microbiology, vol. 43, no. 4, pp. 275-285, 1996
65. A. Acosta-Serrano, I. C. Almeida, L. H. Freitas-Junior, N. Yoshida, and S. Schenkman, "The mucin-like glycoprotein super-family of Trypanosoma cruzi: structure and biological roles" Molecular and Biochemical Parasitology, vol. 114, no. 2, pp. 143-150, 2001
66. J.O. Previato, C. Jones, L. P. B. Goncalves, R. Wait, L. R. Travassos, and L. Mendonca-Previato, "O-glycosidically linked Nacetylglucosamine-bound oligosaccharides from glycoproteins of Trypanosoma cruzi" Biochemical Journal, vol. 301, part 1, pp. 151-159, 1994
67. J.M. DiNoia, G. D. Pollevick, M. T. Xavier et al., "Highdiversity in mucin genes and mucin molecules in Trypanosoma cruzi" The Journal of Biological Chemistry, vol. 271, no. 50, pp. 32078-32083, 1996
68. L. Mendonca-Previato, A. R. Todeschini, N. Heise, O. A. Agrellos, W. B. Dias, and J. O. Previato, "Chemical structure of major glycoconjugates from parasites" Current Organic Chemistry, vol. 12, no. 11, pp. 926-939, 2008
69. J. O. Previato, A. F. B. Andrade, M. C. V. Pessolani, and L. Mendonca-Previato, "Incorporation of sialic acid into Trypanosoma cruzi macromolecules: a proposal for a new metabolic route" Molecular and Biochemical Parasitology, vol. 16, no. 1, pp. 85-96, 1985
70. L. Mendonca-Previato, A. R. Todeschini, L. Freire de Lima, and J. O. Previato, "The trans-sialidase fromTrypanosoma cruzi a putative target for Trypanocidal agents" Open Parasitology Journal, vol. 4, no. 1, pp. 111-115, 2010
71. I. C. Almeida, M. A. J. Ferguson, S. Schenkman, and L. R. Travassos, "Lytic anti-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositolanchored glycoproteins of Trypanosoma cruzi" Biochemical Journal, vol. 304, no. 3, pp. 793-802, 1994
72. S. Schenkman, M.-S. Jiang, G. W. Hart, and V. Nussenzweig, "A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion ofmammalian cells" Cell, vol. 65, no. 7, pp. 1117-1125, 1991
73. R. A. Mortara, S. da Silva, M. F. Araguth, S. A. Blanco, and N. Yoshida, "Polymorphism of the 35-and 50-kilodalton surface glycoconjugates of Trypanosoma cruzi metacyclic trypomastigotes" Infection and Immunity, vol. 60, no. 11, pp. 4673-4678, 1992
74. C. Cortez, N. Yoshida, D. Bahia, and T. J. P. Sobreira, "Structural basis of the interaction of a Trypanosoma cruzi surface molecule implicated in oral infection with host cells and gastric mucin" PLoS ONE, vol. 7, no. 7, Article ID e42153, 2012
75. M. M. Camargo, I. C. Almeida, M. E. S. Pereira, M. A. J. Ferguson, L. R. Travassos, and R. T. Gazzinelli, "Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes initiate the synthesis of proinflammatory cytokines by macrophages" The Journal of Immunology, vol. 158, no. 12, pp. 5890-5901, 1997
76. F. Villalta, C. M. Smith, A. Ruiz-Ruano, and M. F. Lima, "A ligand that Trypanosoma cruzi uses to bind to mammalian cells to initiate infection" FEBS Letters, vol. 505, no. 3, pp. 383-388, 2001
77. R. Giordano, R. Chammas, S. S. Veiga, W. Colli, and M. J. M. Alves, "An acidic component of the heterogeneousTc-85 protein family from the surface of Trypanosoma cruzi is a laminin binding glycoprotein" Molecular and Biochemical Parasitology, vol. 65, no. 1, pp. 85-94, 1994
78. M. H. Magdesian, R. R. Tonelli, M. R. Fessel et al., "A conserved domain of the gp85/trans-sialidase family activates host cell extracellular signal-regulated kinase and facilitates Trypanosoma cruzi infection" Experimental Cell Research, vol. 313, no. 1, pp. 210-218, 2007
79. W. B. Dias, F. D. Fajardo, A. V. Graca-Souza et al., "Endothelial cell signalling induced by trans-sialidase from Trypanosoma cruzi" Cellular Microbiology, vol. 10, no. 1, pp. 88-99, 2008
80. M. H. Magdesian, R. Giordano, H. Ulrich et al., "Infection by Trypanosoma cruzi: identification of a parasite ligand and its host cell receptor"The Journal of Biological Chemistry, vol. 276, no. 22, pp. 19382-19389, 2001
81. N. Yoshida, S. A. Blanco, M. F. Araguth, and J. González, "The stage-specific 90-kilodalton surface antigen of metacyclic trypomastigotes of Trypanosoma cruzi"Molecular and Biochemical Parasitology, vol. 39, no. 1, pp. 39-46, 1990
82. S. Schenkman, N. W. Andrews, V. Nussenzweig, and E. S. Robbins, "Trypanosoma cruzi invade a mammalian epithelial cell in a polarized manner" Cell, vol. 55, no. 1, pp. 157-165, 1988
83. M. L. S. Guther, M. L. C. De Almeida, N. Yoshida, and M. A. J. Ferguson, "Structural studies on the glycosylphosphatidylinositol membrane anchor of Trypanosoma cruzi 1G7-Antigen. The structure of the glycan core" Journal of Biological Chemistry, vol. 267, no. 10, pp. 6820-6828, 1992
84. J. Scharfstein, V. Schmitz, V. Morandi et al., "Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B2 receptors" Journal of Experimental Medicine, vol. 192, no. 9, pp. 1289-1300, 2000
85. A. C. M. Murta, P. M. Persechini, T. De Souto Padron, W. De Souza, J. A. Guimaraes, and J. Scharfstein, "Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase" Molecular and Biochemical Parasitology, vol. 43, no. 1, pp. 27-38, 1990
86. T. Souto-Padron, O. E. Campetella, J. J. Cazzulo, and W. de Souza, "Cysteine proteinase in Trypanosoma cruzi: immunocytochemical localization and involvement in parasite-host cell interaction" Journal of Cell Science, vol. 96, part 3, pp. 485-490, 1990
87. M. N. L. Meirelles, L. Juliano, E. Carmona et al., "Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro" Molecular and Biochemical Parasitology, vol. 52, no. 2, pp. 175-184, 1992
88. M. D. Hazenberg and H. Spits, "Human innate lymphoid cells" Blood, vol. 124, no. 5, pp. 700-709, 2014
89. H. Spits, D. Artis, M. Colonna et al., "Innate lymphoid cells-A proposal for uniform nomenclature" Nature Reviews Immunology, vol. 13, no. 2, pp. 145-149, 2013
90. C. S. N. Klose, M. Flach, L. Möhle et al., "Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages" Cell, vol. 157, no. 2, pp. 340-356, 2014
91. D. Schenten and R. Medzhitov, "The control of adaptive immune responses by the innate immune system" Advances in Immunology, vol. 109, pp. 87-124, 2011
92. C. Olive, "Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants" Expert Review of Vaccines, vol. 11, no. 2, pp. 237-256, 2012
93. R. Medzhitov and C. A. Janeway Jr., "Innate immune recognition and control of adaptive immune responses" Seminars in Immunology, vol. 10, no. 5, pp. 351-353, 1998
94. A. Iwasaki and R. Medzhitov, "Regulation of adaptive immunity by the innate immune system" Science, vol. 327, no. 5963, pp. 291-295, 2010
95. J. J. O' Shea and W. E. Paul, "Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells" Science, vol. 327, no. 5969, pp. 1098-1102, 2010
96. J. E. Allen and R. M. Maizels, "Diversity and dialogue in immunity to helminths" Nature Reviews Immunology, vol. 11, no. 6, pp. 375-388, 2011
97. B. Pulendran and D. Artis, "New paradigms in type 2 immunity" Science, vol. 337, no. 6093, pp. 431-435, 2012
98. L. Y. Drake, K. Iijima, and H. Kita, "Group 2 innate lymphoid cells and CD4+ T cells cooperate to mediate type 2 immune response in mice" Allergy, 2014
99. A. Mizoguchi and A. K. Bhan, "A case for regulatory B cells" Journal of Immunology, vol. 176, no. 2, pp. 705-710, 2006
100. D. J. Dilillo, T. Matsushita, and T. F. Tedder, "B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer" Annals of the New York Academy of Sciences, vol. 1183, pp. 38-57, 2010
101. D. A. A. Vignali, L. W. Collison, and C. J. Workman, "How regulatory T cells work" Nature Reviews Immunology, vol. 8, no. 7, pp. 523-532, 2008
102. J. Banchereau, V. Pascual, and A. O' Garra, "From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines" Nature Immunology, vol. 13, no. 10, pp. 925-931, 2012
103. D. McMahon-Pratt and J. Alexander, "Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunological Reviews, vol. 201, pp. 206-224, 2004
104. M. M. Kane and D. M. Mosser, "Leishmania parasites and their ploys to disrupt macrophage activation" Current Opinion in Hematology, vol. 7, no. 1, pp. 26-31, 2000
105. J. A. D. O. Guerra, S. R. Prestes, H. Silveira et al., "Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon" PLoS Neglected Tropical Diseases, vol. 5, no. 3, p. e980, 2011
106. P. D. Marsden, "Mucosal leishmaniasis ("spundia Escomel, 1911)" Transactions of the Royal Society of TropicalMedicine and Hygiene, vol. 80, no. 6, pp. 859-876, 1986
107. C. Ronet, Y. Hauyon-La Torre, M. Revaz-Breton et al., "Regulatory B cells shape the development ofTh2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production" Journal of Immunology, vol. 184, no. 2, pp. 886-894, 2010
108. A. Gomes-Silva, R. de Cássia Bittar, R. dos Santos Nogueira et al., "Can interferon-and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? Clinical & Experimental Immunology, vol. 149, no. 3, pp. 440-444, 2007
109. P. I. Tarr, R. F. Aline Jr., B. L. Smiley, J. Scholler, J. Keithly, and K. Stuart, "LR1: a candidate RNA virus of Leishmania" Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 24, pp. 9572-9275, 1988
110. G. Widmer, A.M. Comeau, D. B. Furlong, D. F. Wirth, and J. L. Patterson, "Characterization of a RNA virus from the parasite Leishmania" Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 15, pp. 5979-5982, 1989
111. G. Salinas, M. Zamora, K. Stuart, and N. Saravia, "Leishmania RNA viruses in Leishmania of the Viannia subgenus" The American Journal of Tropical Medicine andHygiene, vol. 54, no. 4, pp. 425-429, 1996
112. A. Ives, C. Ronet, F. Prevel et al., "Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis" Science, vol. 331, no. 6018, pp. 775-778, 2011
113. C. Ronet, S. M. Beverley, and N. Fasel, "Muco-cutaneous leishmaniasis in the New World: the ultimate subversion" Virulence, vol. 2, no. 6, pp. 547-552, 2011
114. M. Rayamajhi, J. Humann, S. Kearney, K. K. Hill, and L. L. Lenz, "Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infections" Virulence, vol. 1, no. 5, pp. 418-422, 2010
115. M.-A. Hartley, C. Ronet, H. Zangger, S. M. Beverley, and N. Fasel, "Leishmania RNA virus: when the host pays the toll" Frontiers in Cellular and Infection Microbiology, vol. 2, p. 99, 2012
116. C. M. V. Vendrame, L. D. Souza, M. D. T. Carvalho, K. Salgado, E. M. Carvalho, and H. Goto, "Insulin-like growth factor-I induced and constitutive arginase activity differs among isolates of Leishmania derived from patients with diverse clinical forms of Leishmania braziliensis infection" Transactions of the Royal Society of TropicalMedicine andHygiene, vol. 104, no.8, pp. 566-568, 2010
117. H. E. Cummings, R. Tuladhar, and A. R. Satoskar, "Cytokines and their STATs in cutaneous and visceral leishmaniasis" Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 294389, 6 pages, 2010
118. J. Liese, U. Schleicher, and C. Bogdan, "The innate immune response against Leishmania parasites" Immunobiology, vol. 213, no. 3-4, pp. 377-387, 2008
119. A. Bafica, H. C. Santiago, R. Goldszmid, C. Ropert, R. T. Gazzinelli, and A. Sher, "Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection" Journal of Immunology, vol. 177, no. 6, pp. 3515-3519, 2006
120. R. Koga, S. Hamano, H. Kuwata et al., "TLR-dependent induction of IFN-mediates host defense against Trypanosoma cruzi" Journal of Immunology, vol. 177, no. 10, pp. 7059-7066, 2006
121. A. C. Monteiro, V. Schmitz, E. Svensjo et al., "Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1immunity in amousemodel of subcutaneous infection by Trypanosoma cruzi" Journal of Immunology, vol. 177, no. 9, pp. 6325-6335, 2006
122. C. Bern, D. L. Martin, and R. H. Gilman, "Acute and congenital Chagas disease" Advances in Parasitology, vol. 75, pp. 19-47, 2011
123. M. Samudio, S. Montenegro-James, M. Cabral, J. Martinez, A. R. De Arias, and M. A. James, "Cytokine responses in Trypanosoma cruzi-infected children in Paraguay" The American Journal of Tropical Medicine andHygiene, vol. 58, no. 1, pp. 119-121, 1998
124. E. Moretti, B. Basso, L. Cervetta, A. Brigada, and G. Barbieri, "Patterns of cytokines and soluble cellular receptors in the sera of children with acute Chagas' disease" Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 6, pp. 1324-1327, 2002
125. I. C. Almeida, M. M. Camargo, D. O. Procópio et al., "Highly purified glycosylphosphatidylinositols fromTrypanosoma cruzi are potent proinflammatory agents" EMBO Journal, vol. 19, no. 7, pp. 1476-1485, 2000
126. J. C. S. Aliberti, J. T. Souto, A. P. M. P. Marino et al., "Modulation of chemokine production and inflammatory responses in interferon-and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection" The American Journal of Pathology, vol. 158, no. 4, pp. 1433-1440, 2001
127. I. C. Almeida and R. T. Gazzinelli, "Proinflammatory activity of glycosylphosphatidylinositol anchors derived from Trypanosoma cruzi: structural and functional analyses" Journal of Leukocyte Biology, vol. 70, no. 4, pp. 467-477, 2001
128. I. A. Abrahamsohn and R. L. Coffman, "Trypanosoma cruzi: IL-10, TNF, IFN-And IL-12 regulate innate and acquired immunity to infection" Experimental Parasitology, vol. 84, no. 2, pp. 231-244, 1996
129. M. S. Duthie and S. J. Kahn, "During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single-galactosylceramide treatment" Immunology, vol. 119, no. 3, pp. 355-361, 2006
130. M. A. Munoz-Fernández and M. Fresno, "Activation of human macrophages for the killing of intracellular Trypanosoma cruzi by TNF-and IFN-through a nitric oxide-dependent mechanism" Immunology Letters, vol. 33, no. 1, pp. 35-40, 1992
131. M. A. Munoz-Fernández and M. Fresno, "Synergism between tumor necrosis factor- and interferon- on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism" European Journal of Immunology, vol. 22, no. 2, pp. 301-307, 1992
132. R. L. Cardoni, "La respuesta inflamatoria en la infección aguda con Trypanosoma cruzi" Medicina, vol. 57, no. 2, pp. 227-234, 1997
133. G. A. DosReis, "Cell-mediated immunity in experimental Trypanosoma cruzi infection" Parasitology Today, vol. 13, no. 9, pp. 335-342, 1997
134. G. A. Martins, M. A. G. Cardoso, J. C. S. Aliberti, and J. S. Silva, "Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice" Immunology Letters, vol. 63, no. 2, pp. 113-120, 1998
135. R. C. N. Melo, D. L. Fabrino, H. D' Avila, H. C. Teixeira, and A. P. Ferreira, "Production of hydrogen peroxide by peripheral blood monocytes and specific macrophages during experimental infection with Trypanosoma cruzi in vivo" Cell Biology International, vol. 27, no. 10, pp. 853-861, 2003
136. Y. Miyahira, "Trypanosoma cruzi infection from the view of CD8+ T cell immunity-An infection model for developing T cell vaccine" Parasitology International, vol. 57, no. 1, pp. 38-48, 2008
137. A. M. Padilla, J. M. Bustamante, and R. L. Tarleton, "CD8+ T cells in Trypanosoma cruzi infection" Current Opinion in Immunology, vol. 21, no. 4, pp. 385-390, 2009
138. C. Junqueira, B. Caetano, D. C. Bartholomeu et al., "Theendless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease" Expert Reviews in Molecular Medicine, vol. 12, article e29, 2010
139. G. M. Krautz, J. C. Kissinger, and A. U. Krettli, "The targets of the lytic antibody response against Trypanosoma cruzi" Parasitology Today, vol. 16, no. 1, pp. 31-34, 2000
140. W. O. Dutra, M. O. C. Rocha, and M. M. Teixeira, "The clinical immunology of human Chagas disease" Trends in Parasitology, vol. 21, no. 12, pp. 581-587, 2005
141. F. F. de Araujo, R. Correa-Oliveira, M. O. C. Rocha et al., "Foxp3+ CD25high CD4+ regulatory T cells from indeterminate patients with Chagas disease can suppress the effector cells and cytokines and reveal altered correlations with disease severity" Immunobiology, vol. 217, no. 8, pp. 768-777, 2012
142. A.M. C. Sartori, M. H. Lopes, B. Caramelli et al., "Simultaneous occurrence of acutemyocarditis and reactivatedChagas' disease in a patient with AIDS" Clinical Infectious Diseases, vol. 21, no. 5, pp. 1297-1299, 1995
143. D. R. Almeida, A. C. Carvalho, J. N. Branco et al., "Chagas' disease reactivation after heart transplantation: efficacy of allopurinol treatment" The Journal of Heart and Lung Transplantation, vol. 15, no. 10, pp. 988-992, 1996
144. R. L. Tarleton, M. J. Grusby, M. Postan, and L. H. Glimcher, "Trypanosoma cruzi infection in MHC-deficient mice: Further evidence for the role of both class I-and class II-restrictedTcells in immune resistance and disease" International Immunology, vol. 8, no. 1, pp. 13-22, 1996
145. B. Reina-San-Mart?n, A. Cosson, and P. Minoprio, "Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents" Parasitology Today, vol. 16, no. 2, pp. 62-67, 2000
146. B. Reina-San-Mart?n, W. Degrave, C. Rougeot et al., "A B-cell mitogen froma pathogenic trypanosome is a eukaryotic proline racemase" Nature Medicine, vol. 6, no. 8, pp. 890-897, 2000
147. E. Ansa-Addo and J. Inal, "T. cruzi interference with host cell membrane integrity triggers the release of Plasma Membranederived Vesicles: a mechanism for entry into mammalian cells" The Journal of Immunology, vol. 148, p. 5, 2010
148. S. Zambrano-Villa, D. Rosales-Borjas, J. C. Carrero, and L. Ortiz-Ortiz, "How protozoan parasites evade the immune response" Trends in Parasitology, vol. 18, no. 6, pp. 272-278, 2002
149. I. Cestari, E. Ansa-Addo, P. Deolindo, J. M. Inal, and M. I. Ramirez, "Trypanosoma cruzi immune evasion mediated by host cell-derived microvesicles" Journal of Immunology, vol. 188, no. 4, pp. 1942-1952, 2012
150. T. C. Araujo-Jorge, M. C. Waghabi, M. D. N. C. Soeiro, M. Keramidas, S. Bailly, and J.-J. Feige, "Pivotal role for TGF- in infectious heart disease: the case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy" Cytokine and Growth Factor Reviews, vol. 19, no. 5-6, pp. 405-413, 2008
151. M. Abu-Shakra, D. Buskila, and Y. Shoenfeld, "Molecular mimicry between host and pathogen: examples from parasites and implication" Immunology Letters, vol. 67, no. 2, pp. 147-152, 1999
152. W. Savino, M. Do Carmo Leite-de-Moraes, M. Hontebeyrie-Joskowicz, and M. Dardenne, "Studies on the thymus in Chagas' disease. I. Changes in the thymic microenvironment in mice acutely infected with Trypanosoma cruzi" European Journal of Immunology, vol. 19, no. 9, pp. 1727-1733, 1989
153. A. F. F. R. Nardy, J. Luiz da Silva Filho, A. R. Pérez et al., "Transsialidase from Trypanosoma cruzi enhances the adhesion properties and fibronectin-driven migration of thymocytes" Microbes and Infection, vol. 15, no. 5, pp. 365-374, 2013
154. Y. E. Latchman, S. C. Liang, Y. Wu et al., "PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells" Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10691-10696, 2004
155. L. I. Terrazas, D. Montero, C. A. Terrazas, J. L. Reyes, and M. Rodr?guez-Sosa, "Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis" International Journal for Parasitology, vol. 35, no. 13, pp. 1349-1358, 2005
156. L. R. Dulgerian, V. V. Garrido, C. C. Stempin, and F.M. Cerbán, "Programmed death ligand 2 regulates arginase induction and modifies Trypanosoma cruzi survival in macrophages during murine experimental infection" Immunology, vol. 133, no. 1, pp. 29-40, 2011
157. H. D'Avila, C. G. Freire-de-Lima, N. R. Roque et al., "Host cell lipid bodies triggered by Trypanosoma cruzi infection and enhanced by the uptake of apoptotic cells are associated with prostaglandin E2 generation and increased parasite growth" Journal of Infectious Diseases, vol. 204, no. 6, pp. 951-961, 2011
158. S. M. Puentes, R. P. Da Silva, D. L. Sacks, C. H. Hammer, and K. A. Joiner, "Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9" The Journal of Immunology, vol. 145, no. 12, pp. 4311-4316, 1990
159. T. Hermoso, Z. Fishelson, S. I. Becker, K. Hirschberg, and C. L. Jaffe, "Leishmanial protein kinases phosphorylate components of the complement system" The EMBO Journal, vol. 10, no. 13, pp. 4061-4067, 1991
160. A. Brittingham, C. J. Morrison, W.R. McMaster, B. S. McGwire, K.-P. Chang, and D.M. Mosser, "Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis" Journal of Immunology, vol. 155, no. 6, pp. 3102-3111, 1995
161. D. Sacks and A. Sher, "Evasion of innate immunity by parasitic protozoa"Nature Immunology, vol. 3, no. 11, pp. 1041-1047, 2002
162. M. M. Kulkarni, W. R. McMaster, E. Kamysz, W. Kamysz, D. M. Engman, and B. S. McGwire, "The major surfacemetalloprotease of the parasitic protozoan, Leishmania, protects against antimicrobial peptide-induced apoptotic killing" Molecular Microbiology, vol. 62, no. 5, pp. 1484-1497, 2006
163. A. T. Remaley, D. B. Kuhns, R. E. Basford, R. H. Glew, and S. S. Kaplan, "Leishmanial phosphatase blocks neutrophil O2-production"The Journal of Biological Chemistry, vol. 259, no. 18, pp. 11173-11175, 1984
164. P. Gueirard, A. Laplante, C. Rondeau, G. Milon, and M. Desjardins, "Trafficking of Leishmania donovani promastigotes in non-lytic compartments in neutrophils enables the subsequent transfer of parasites tomacrophages" CellularMicrobiology, vol. 10, no. 1, pp. 100-111, 2008
165. A. S. A. Tuwaijri, I. A. A. Mofleh, and A. A. Mahmoud, "Effect of Leishmania major on human polymorphonuclear leucocyte function in vitro" Journal ofMedicalMicrobiology, vol. 32, no. 3, pp. 189-193, 1990
166. G. Van Zandbergen, N. Hermann, H. Laufs, W. Solbach, and T. Laskay, "Leishmania promastigotes release a granulocyte chemotactic factor and induce interleukin-8 release but inhibit gamma interferon-inducible protein 10 production by neutrophil granulocytes" Infection and Immunity, vol. 70, no. 8, pp. 4177-4184, 2002
167. A. Wenzel and G. Van Zandbergen, "Lipoxin A4 receptor dependent leishmania infection" Autoimmunity, vol. 42, no. 4, pp. 331-333, 2009
168. M. S. Faria, F. C. G. Reis, R. L. Azevedo-Pereira, L. S. Morrison, J. C. Mottram, and A. P. C. A. Lima, "Leishmania inhibitor of serine peptidase 2 prevents TLR4 activation by neutrophil elastase promoting parasite survival in murine macrophages" The Journal of Immunology, vol. 186, no. 1, pp. 411-422, 2011
169. B. John and C. A. Hunter, "Immunology: neutrophil soldiers or Trojan horses? Science, vol. 321, no. 5891, pp. 917-918, 2008
170. G. Van Zandbergen, A. Bollinger, A. Wenzel et al., "Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum" Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 37, pp. 13837-13842, 2006
171. R. M. Locksley, F. P. Heinzel, J. E. Fankhauser, C. S. Nelson, and M. D. Sadick, "Cutaneous host defense in leishmaniasis: Interaction of isolated dermal macrophages and epidermal Langerhans cells with the insect-stage promastigote" Infection and Immunity, vol. 56, no. 2, pp. 336-342, 1988
172. C. Bogdan, N. Donhauser, R. Döring, M. Röllinghoff, A. Diefenbach, and M. G. Rittig, "Fibroblasts as host cells in latent leishmaniosis" Journal of ExperimentalMedicine, vol. 191, no. 12, pp. 2121-2129, 2000
173. C. Bogdan and M. Röllinghoff, "The immune response to Leishmania: mechanisms of parasite control and evasion" International Journal for Parasitology, vol. 28, no. 1, pp. 121-134, 1998
174. A. Descoteaux and S. J. Turco, "Glycoconjugates in Leishmania infectivity" Biochimica et Biophysica Acta, vol. 1455, no. 2-3, pp. 341-352, 1999
175. M. T. Shio, K. Hassani, A. Isnard et al., "Host cell signalling and leishmania mechanisms of evasion" Journal of Tropical Medicine, vol. 2012, Article ID 819512, 14 pages, 2012
176. C. Bogdan, M. Rollinghoff, andW. Solbach, "Evasion strategies of Leishmania parasites" Parasitology Today, vol. 6, no. 6, pp. 183-187, 1990
177. M. A. Gomez, I. Contreras, M. Hallé, M. L. Tremblay, R. W. McMaster, and M. Olivier, "LeishmaniaGP63 alters host signaling through cleavage-Activated protein tyrosine phosphatases" Science Signaling, vol. 2, no. 90, p. ra58, 2009
178. S. Ghosh, S. Bhattacharyya, S. Das et al., "Generation of ceramide in murine macrophages infected with Leishmania donovani alters macrophage signaling events and aids intracellular parasitic survival" Molecular and Cellular Biochemistry, vol. 223, no. 1-2, pp. 47-60, 2001
179. S. Ghosh, S. Bhattacharyya, M. Sirkar et al., "Leishmania donovani suppresses activated protein 1 and NF-B activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase" Infection and Immunity, vol. 70, no. 12, pp. 6828-6838, 2002
180. D. J. Gregory, M. Godbout, I. Contreras, G. Forget, and M. Olivier, "A novel formofNF-B is induced by Leishmania infection: involvement in macrophage gene expression" European Journal of Immunology, vol. 38, no. 4, pp. 1071-1081, 2008
181. B. M. Neves, R. Silvestre, M. Resende et al., "Activation of phosphatidylinositol 3-kinase/akt and impairment of nuclear factor-B: Molecular mechanisms behind the arrested maturation/ activation state of leishmania infantum-infected dendritic cells" The American Journal of Pathology, vol. 177, no. 6, pp. 2898-2911, 2010
182. G. Forget, D. J. Gregory, andM. Olivier, "Proteasome-mediated degradation of STAT1 following infection of macrophages with Leishmania donovani" The Journal of Biological Chemistry, vol. 280, no. 34, pp. 30542-30549, 2005
183. M. Olivier, D. J. Gregory, and G. Forget, "Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view" Clinical Microbiology Reviews, vol. 18, no. 2, pp. 293-305, 2005
184. M. P. Barrett, J. C. Mottram, and G. H. Coombs, "Recent advances in identifying and validating drug targets in trypanosomes and leishmanias" Trends in Microbiology, vol. 7, no. 2, pp. 82-88, 1999
185. S. H. Lee, J. L. Stephens, K. S. Paul, andP.T. Englund, "Fatty acid synthesis by elongases in trypanosomes" Cell, vol. 126, no. 4, pp. 691-699, 2006
186. P. A. M. Michels, F. Bringaud, M. Herman, and V. Hannaert, "Metabolic functions of glycosomes in trypanosomatids" Biochimica et Biophysica Acta, vol. 1763, no. 12, pp. 1463-1477, 2006
187. M. H. El Kouni, "Potential chemotherapeutic targets in the purine metabolism of parasites" Pharmacology and Therapeutics, vol. 99, no. 3, pp. 283-309, 2003
188. S. Muller, E. Liebau, R. D. Walter, and R. L. Krauth-Siegel, "Thiol-based redox metabolism of protozoan parasites" Trends in Parasitology, vol. 19, no. 7, pp. 320-328, 2003
189. T. C. Hammarton, J. Clark, F. Douglas, M. Boshart, and J. C. Mottram, "Stage-specific differences in cell cycle control in Trypanosoma brucei revealed by RNA interference of a mitotic cyclin"The Journal of Biological Chemistry, vol. 278, no. 25, pp. 22877-22886, 2003
190. K. A. Werbovetz and R. E. Morgan, "Selective lead compounds against kinetoplastid tubulin" Advances in Experimental Medicine and Biology, vol. 625, pp. 33-47, 2008
191. D. Savoia, T. Allice, and P.-A. Tovo, "Antileishmanial activity of HIV protease inhibitors" International Journal of Antimicrobial Agents, vol. 26, no. 1, pp. 92-94, 2005
192. J. Nkemgu-Njinkeng, V. Rosenkranz, M. Wink, and D. Steverding, "Antitrypanosomal activities of proteasome inhibitors" Antimicrobial Agents and Chemotherapy, vol. 46, no. 6, pp. 2038-2040, 2002
193. R. J. Glenn, A. J. Pemberton, H. J. Royle et al., "Trypanocidal effect of alpha, beta-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity" International Journal of Antimicrobial Agents, vol. 24, no. 3, pp. 286-289, 2004
194. S. R. Wilkinson, M. C. Taylor, D. Horn, J. M. Kelly, and I. Cheeseman, "A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes" Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 13, pp. 5022-5027, 2008
195. S. Patterson and S. Wyllie, "Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects" Trends in Parasitology, vol. 30, no. 6, pp. 289-298, 2014
196. M. T. Bahia, I.M. de Andrade, T. A. F. Martins et al., "Fexinidazole: a potential new drug candidate for chagas disease" PLoS Neglected Tropical Diseases, vol. 6, no. 11, Article ID e1870, 2012
197. M. T. Bahia, A. F. Nascimento, A. L. Mazzeti et al., "Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for chagas disease" Antimicrobial Agents and Chemotherapy, vol. 58, pp. 4362-4370, 2014
198. Y. Zhou, N. Messier, M. Ouellette, B. P. Rosen, and R. Mukhopadhyay, "Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug Pentostam" The Journal of Biological Chemistry, vol. 279, no. 36, pp. 37445-37451, 2004
199. V. S. Amato, F. F. Tuon, H. A. Bacha, V. A. Neto, and A. C. Nicodemo, "Mucosal leishmaniasis. Current scenario and prospects for treatment" Acta Tropica, vol. 105, no. 1, pp. 1-9, 2008
200. J. Golenser and A. Domb, "New formulations and derivatives of amphotericin B for treatment of leishmaniasis" Mini-Reviews in Medicinal Chemistry, vol. 6, no. 2, pp. 153-162, 2006
201. F. Chappuis, S. Sundar, A. Hailu et al., "Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nature Reviews Microbiology, vol. 5, no. 11, pp. 873-882, 2007
202. P. Chugh, B. Bradel-Tretheway, C. M. R. Monteiro-Filho et al., "Akt inhibitors as an HIV-1 infected macrophage-specific antiviral therapy" Retrovirology, vol. 5, article 11, 2008
203. J. J. Berman, "Treatment of leishmaniasis withmiltefosine: 2008 status" Expert Opinion on DrugMetabolismand Toxicology, vol. 4, no. 9, pp. 1209-1216, 2008
204. T. Sun and Y. Zhang, "Pentamidine binds to tRNAthrough nonspecific hydrophobic interactions and inhibits aminoacylation and translation" Nucleic Acids Research, vol. 36, no. 5, pp. 1654-1664, 2008
205. B. Chawla, A. Jhingran, A. Panigrahi, K. D. Stuart, and R. Madhubala, "Paromomycin affects translation and vesiclemediated trafficking as revealed by proteomics of paromomycin-susceptible-resistant leishmania donovani" PLoS ONE, vol. 6, no. 10, Article ID e26660, 2011
206. J. Soto, J. Tolado, L. Valda et al., "Treatment of bolivianmucosal leishmaniasis withmiltefosine" Clinical Infectious Diseases, vol. 44, no. 3, pp. 350-356, 2007
207. M. Baginski and J. Czub, "Amphotericin B and its new derivatives-mode of action" Current DrugMetabolism, vol. 10, no. 5, pp. 459-469, 2009
208. S. Sundar and J. Chakravarty, "Leishmaniasis: an update of current pharmacotherapy" Expert Opinion on Pharmacotherapy, vol. 14, no. 1, pp. 53-63, 2013
209. S. Sundar, P. K. Sinha, S. A. Dixon et al., "Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India"TheAmericanJournal of TropicalMedicine and Hygiene, vol. 84, no. 6, pp. 892-900, 2011
210. P. M. Loiseau, S. Cojean, and J. Schrével, "Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance" Parasite, vol. 18, no. 2, pp. 115-119, 2011
211. J. A. Urbina, "Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites" Parasitology, vol. 114, pp. S91-S99, 1997
212. G. I. Lepesheva, F. Villalta, and M. R. Waterman, "Targeting Trypanosoma cruzi Sterol 14-demethylase (CYP51)" Advances in Parasitology, vol. 75, pp. 65-87, 2011
213. W. de Souza and J. C. Rodrigues, "Sterol biosynthesis pathway as target for anti-trypanosomatid drugs" Interdisciplinary Perspectives on Infectious Diseases, vol. 2009, Article ID 642502, 19 pages, 2009
214. A. Khatami, A. Firooz, F. Gorouhi, and Y. Dowlati, "Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials" Journal of the American Academy of Dermatology, vol. 57, no. 2, pp. 335.e1-335.e29, 2007
215. R. Ramanathan, K.R. Talaat, D. P. Fedorko, S. Mahanty, andT.E. Nash, "A species-specific approach to the use of non-Antimony treatments for cutaneous leishmaniasis" The American Journal of TropicalMedicine andHygiene, vol. 84, no. 1, pp. 109-117, 2011
216. A. Q. Sousa, M. S. Frutuoso, E. A. Moraes, R. D. Pearson, and M. M. L. Pompeu, "High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to leishmania (vianna) Braziliensis" Clinical Infectious Diseases, vol. 53, no. 7, pp. 693-695, 2011
217. V. G. Duschak, "A decade of targets and patented drugs for chemotherapy of chagas disease" Recent Patents on Anti-Infective Drug Discovery, vol. 6, no. 3, pp. 216-259, 2011
218. F. S. Buckner and J. A. Urbina, "Recent developments in sterol 14-demethylase inhibitors for Chagas disease" International Journal for Parasitology: Drugs and Drug Resistance, vol. 2, pp. 236-242, 2012
219. I. Molina, J. Gómez I Prat, F. Salvador et al., "Randomized trial of posaconazole and benznidazole for chronic Chagas' disease" The New England Journal ofMedicine, vol. 370, no. 20, pp. 1899-1908, 2014
220. N. Chamond, M. Goytia, N. Coatnoan et al., "Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity" Molecular Microbiology, vol. 58, no. 1, pp. 46-60, 2005
221. A. Berneman, L. Montout, S. Goyard et al., "Combined approaches for drug design points the way to novel proline racemase inhibitor candidates to fight chagas' disease" PLoS ONE, vol. 8, no. 4, Article ID e60955, 2013
222. E. Pozio, "Hiqhly active anti-retroviral therapy and opportunistic protozoan infections" Parassitologia, vol. 46, no. 1-2, pp. 89-93, 2004
223. G. Abbenante and D. P. Fairlie, "Protease inhibitors in the clinic" Medicinal Chemistry, vol. 1, no. 1, pp. 71-104, 2005
224. L. O. Santos, B. S. Vitório, M. H. Branquinha, C. M. Pedroso e silva, A. L. S. Santos, and C. M. D'avila-Levy, "Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients" Journal of Antimicrobial Chemotherapy, vol. 68, no. 2, Article ID dks410, pp. 348-353, 2013
225. L. O. Santos, A. S. Garcia-Gomes, M. Catanho et al., "Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy" Current Medicinal Chemistry, vol. 20, no. 25, pp. 3116-3133, 2013
226. S. L. Croft, S. Sundar, and A. H. Fairlamb, "Drug resistance in leishmaniasis" Clinical Microbiology Reviews, vol. 19, no. 1, pp. 111-126, 2006
227. A. Martinelli, R. Moreira, and P. V. L. Cravo, "Malaria combination therapies: advantages and shortcomings" Mini-Reviews in Medicinal Chemistry, vol. 8, no. 3, pp. 201-212, 2008
228. L. L. Silver, "Multi-targeting by monotherapeutic antibacterials" Nature ReviewsDrugDiscovery, vol. 6, no. 1, pp. 41-55, 2007
229. A. Petrelli and S. Giordano, "From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage" Current Medicinal Chemistry, vol. 15, no. 5, pp. 422-432, 2008
230. B. M. Roatt, R. D. Aguiar-Soares, W. Coura-Vital et al., "Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease" Frontiers in Immunology, vol. 5, p. 272, 2014
231. J. Joshi, N. Malla, and S. Kaur, "A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-An experimental study" Parasitology International, vol. 63, no. 4, pp. 612-620, 2014
232. B. Monge-Maillo and R. López-Vélez, "Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis" Drugs, vol. 73, no. 17, pp. 1889-1920, 2013
233. A. Khamesipour, "Therapeutic vaccines for leishmaniasis" Expert Opinion on BiologicalTherapy, vol. 31, pp. 1-9, 2014